Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML

Blood (2024) 144 (Supplement 1): 53.

https://doi.org/10.1182/blood-2024-211997

Published: 2024

Journal Articles

JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

Blood (2024) 144 (Supplement 1): 4513.

https://doi.org/10.1182/blood-2024-205839

Published: 2024

Journal Articles

The Splicing-Associated Network PAK1-Clk-SRRM1 Is a Critical Vulnerability to Overcome Chemoresistance in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 409.

https://doi.org/10.1182/blood-2023-186264

Published: 2023

Journal Articles

JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms

Blood (2022) 140 (Supplement 1): 795–796.

https://doi.org/10.1182/blood-2022-167719

Published: 2022

Journal Articles

Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

Lina Benajiba, MD PhD, Hetty E. Carraway, MD MBA, Nada Hamad, MB.BS, FRACP, FRCPA, Eytan M. Stein, MD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Amy Burroughs, Scott Harris, Hayley Lane, Dorothy D. Nguyen, MD, Monic Stuart, MD MPH, Jesse Vargas, PhD, Alexandre Puissant, PhD, Kimberly Stegmaier, MD, Courtney D. DiNardo, MD MSCE

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-140636

Published: 2020

Journal Articles

Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia

Reinaldo Dal Bello Figueiras, MD, Justine Pasanisi, Romane Joudinaud, Matthieu Duchmann, Gaetano Sodaro, Clementine Chauvel, Loic Vasseur, MD, Bryann Pardieu, Frank Ling, Kim Pacchiardi, Camille Vaganay, Lionel Faivre, Chaïma Benaksas, Claude Preudhomme, MD PhD, Emmanuel Raffoux, MD, Emmanuelle Clappier, PhD PharmD, Lionel Ades, MDPhD, Alexandre Puissant, PhD, Raphael Itzykson, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137048

Published: 2020

Journal Articles

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Blood (2020) 136 (4): 387–400.

https://doi.org/10.1182/blood.2019003267

Published: 2020

Includes: Supplemental data

Journal Articles

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Blood (2019) 134 (Supplement_1): 877.

https://doi.org/10.1182/blood-2019-131255

Published: 2019

Journal Articles

Creatine Kinase Pathway Inhibition Alters GSK3 and WNT Signaling in EVI1-Positive Acute Myeloid Leukemia

Lina Benajiba, Gabriela Alexe, Olivier Hermine, MD PhD, Michael Hemann, Alexandre Puissant, Kimberly Stegmaier, MD

Blood (2017) 130 (Supplement 1): 1191.

https://doi.org/10.1182/blood.V130.Suppl_1.1191.1191

Published: 2017

Journal Articles

Exploiting an Asp-Glu "Switch" in Glycogen Synthase Kinase 3 to Design Paralog Selective Inhibitors for Acute Myeloid Leukemia Treatment

Blood (2017) 130 (Supplement 1): 2075.

https://doi.org/10.1182/blood.V130.Suppl_1.2075.2075

Published: 2017

Journal Articles

Vcp-Regulated Homologous Recombination Represents a New Druggable Vulnerability in Acute Myeloid Leukemia

Lina Benajiba, Nina Fenouille, Edyta Malolepsza, Jana M Ellegast, MD, Gabriela Alexe, Yana Pikman, MD, Frédéric Luciano, Ilene Galinsky, Daniel J. DeAngelo, MD, Richard M. Stone, MD, Patrick Auberger, PhD, Josee Guirouilh-Barbat, Bernard Lopez, Mehdi Khaled, Kasper Lage, Olivier Hermine, MD PhD, Michael Hemann, Alexandre Puissant, Kimberly Stegmaier, MD

Blood (2017) 130 (Supplement 1): 880.

https://doi.org/10.1182/blood.V130.Suppl_1.880.880

Published: 2017

Journal Articles

Autophagy, a key mechanism of oncogenesis and resistance in leukemia

Patrick Auberger, Alexandre Puissant

Blood (2017) 129 (5): 547–552.

https://doi.org/10.1182/blood-2016-07-692707

Published: 2017

Journal Articles

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Lina Benajiba, Gabriela Alexe, PhD, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Qing Li, MD PhD, Frederic Luciano, PhD, Patrick Auberger, PhD, Ilene Galinsky, MSN, ANPc, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Archibald S. Perkins, MD PhD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2016) 128 (22): 523.

https://doi.org/10.1182/blood.V128.22.523.523

Published: 2016

Journal Articles

Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to Sorafenib in AML

Oscar Lindblad, Eugenio Cordero, Alexandre Puissant, Lucy Macaulay, Nuzhat N. Kabir, Jianmin Sun, Karin Haraldsson, Åke Borg, Fredrik Levander, Kimberly Stegmaier, MD, Kristian Pietras, Lars Ronnstrand, Julhash U. Kazi

Blood (2015) 126 (23): 2472.

https://doi.org/10.1182/blood.V126.23.2472.2472

Published: 2015

Journal Articles

Targeting MTHFD2 in Acute Myeloid Leukemia

Yana Pikman, MD, Alexandre Puissant, PhD, Gabriela Alexe, PhD, Andrew Furman, BA, Stacey Frumm, BA, Linda Ross, PhD, Liying Chen, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Caroline A Lewis, PhD, Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, ANP, Andrew L Kung, MD PhD, Matthew Vader Heiden, MD PhD, Michael T. Hemann, PhD, Versha Banerji, MD, Kimberly Stegmaier, MD

Blood (2015) 126 (23): 443.

https://doi.org/10.1182/blood.V126.23.443.443

Published: 2015

Journal Articles

Identification of CKMT1B As a New Target in EVI1-Positive AML

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Gabriela Alexe, PhD, Lina Benajiba, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2015) 126 (23): 3674.

https://doi.org/10.1182/blood.V126.23.3674.3674

Published: 2015

Journal Articles

Implication of the Anti-Apoptotic Protein Bcl-B (BCL2L10) in the Pathogenesis of Multiple Myeloma

Valentine Richez, Jr., MD, Frederic Luciano, PhD, Amine Hamouda, PhD, Alexandre Puissant, Guillaume Robert, PhD, Arnaud Jacquel, PhD, Thomas Cluzeau, MDPhD, Kenneth C Anderson, MD, Jean-Gabriel Fuzibet, MD, Patrick Auberger, PhD

Blood (2015) 126 (23): 2958.

https://doi.org/10.1182/blood.V126.23.2958.2958

Published: 2015

Journal Articles

MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells

Suiyang Liu, Li Yin, Dina Stroopinsky, Hasan Rajabi, Alexandre Puissant, Kimberly Stegmaier, David Avigan, Surender Kharbanda, Donald Kufe, Richard Stone

Blood (2014) 123 (5): 734–742.

https://doi.org/10.1182/blood-2013-04-493858

Published: 2014

Includes: Supplemental data

Journal Articles

Targeting Folate Metabolism In Acute Myelogenous Leukemia

Yana Pikman, MD, Alexandre Puissant, PhD, Gabriela Alexe, PhD, Stacey M. Frumm, Linda Ross, PhD, Liying Chen, Ph.D., Nina Fenouille, PhD, Christopher F Bassil, Clary B. Clish, PhD, Andrew L Kung, MD, PhD, Michael T Hemann, PhD, Versha Banerji, MD, Kimberly Stegmaier, MD

Blood (2013) 122 (21): 3798.

https://doi.org/10.1182/blood.V122.21.3798.3798

Published: 2013

Journal Articles

BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients

Thomas Cluzeau, MD, PhD, Guillaume Robert, Jean-Michel Karsenti, MD, Frederic Luciano, Alexandre Puissant, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Aline Renneville, MD, Claude Preudhomme, Pierre Fenaux, MD, PhD, Jill-Patrice Cassuto, MD, Sophie Raynaud, Nicolas Mounier, MD, PhD, Patrick Auberger, MD, PhD

Blood (2012) 120 (21): 701.

https://doi.org/10.1182/blood.V120.21.701.701

Published: 2012

NARROW

Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML

JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

The Splicing-Associated Network PAK1-Clk-SRRM1 Is a Critical Vulnerability to Overcome Chemoresistance in Acute Myeloid Leukemia

JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms

Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Creatine Kinase Pathway Inhibition Alters GSK3 and WNT Signaling in EVI1-Positive Acute Myeloid Leukemia

Exploiting an Asp-Glu "Switch" in Glycogen Synthase Kinase 3 to Design Paralog Selective Inhibitors for Acute Myeloid Leukemia Treatment

Vcp-Regulated Homologous Recombination Represents a New Druggable Vulnerability in Acute Myeloid Leukemia

Autophagy, a key mechanism of oncogenesis and resistance in leukemia

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to Sorafenib in AML

Targeting MTHFD2 in Acute Myeloid Leukemia

Identification of CKMT1B As a New Target in EVI1-Positive AML

Implication of the Anti-Apoptotic Protein Bcl-B (BCL2L10) in the Pathogenesis of Multiple Myeloma

MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells

Targeting Folate Metabolism In Acute Myelogenous Leukemia

BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only